Literature DB >> 18628599

Pretreatment of macrophages with the combination of IFN-gamma and IL-12 induces resistance to Leishmania major at the early phase of infection.

Haruko Ota1, Yasuhiro Takashima, Yoshitsugu Matsumoto, Yoshihiro Hayashi, Yasunobu Matsumoto.   

Abstract

Interferon (IFN)-gamma is essential but not sufficient to control leishmaniasis. It is known that IFN-gamma is one of the major macrophage-activating cytokines, and the activated macrophages are a principal source of interleukin (IL)-12, which induces autocrine macrophage activation. In this study, the combined effect of IFN-gamma and IL-12 on the susceptibility of macrophages to Leishmania major infection was evaluated. Macrophages pretreated with IFN-gamma and/or IL-12 were infected with the parasites. Four hr post-infection (p.i.), the levels of infection and parasite load in the macrophages treated with the combination of IFN-gamma and IL-12 (IFN-gamma/IL-12) were significantly lower than those in the nontreated cells. However, the macrophages treated with either IFN-gamma or IL-12 did not show resistance to L. major infection. In addition, 72 hr p.i., the IFN-gamma/IL-12-treated and IFN-gamma-treated macrophages showed significantly lower levels of infection and parasite load than the nontreated cells, and higher levels of resistance was observed in the IFN-gamma/IL-12-treated macrophages than in the IFN-gamma-treated macrophages. Although IFN-gamma/IL-12 treatment of macrophages prior to the infection led to the induction of resistance, as described above, this resistance was not induced when these cytokines and the parasites were added simultaneously to the macrophage culture. These results suggest that IFN-gamma/IL-12 treatment prior to the infection restricts the early phase of the infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628599     DOI: 10.1292/jvms.70.589

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  6 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice.

Authors:  Eduardo Seiji Yamamoto; Bruno Luiz S Campos; Márcia Dalastra Laurenti; João H G Lago; Simone dos Santos Grecco; Carlos E P Corbett; Luiz Felipe D Passero
Journal:  Parasitol Res       Date:  2013-10-31       Impact factor: 2.289

3.  Comparison of Th1 and Th2 responses in non-healing and healing patients with cutaneous leishmaniasis.

Authors:  Maryam Shahi; Masoud Mohajery; Seyyed Ali Akbar Shamsian; Hossein Nahrevanian; Seyyed Mohammad Javad Yazdanpanah
Journal:  Rep Biochem Mol Biol       Date:  2013-04

4.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

Review 5.  Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.

Authors:  Amrita Saha; Souravi Roy; Anindita Ukil
Journal:  Infect Immun       Date:  2022-07-11       Impact factor: 3.609

6.  Optimization of the Timing of Induction for the Assessment of Nitric Oxide Production in Leishmania major Infected Macrophage Cells.

Authors:  Somaye Sadeghi; Negar Seyed; Sima Rafati; Tahereh Taheri
Journal:  Iran J Parasitol       Date:  2016 Jul-Sep       Impact factor: 1.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.